Recent aspects of vasculitis and future direction

Internal Medicine

Volumn 50, Issue 18, 2011, Pages 1869-1877

  Aras, Gülfidan ^a  

^a Yedikule Education and Research Hospital of Chest Diseases   (Turkey)

Author keywords

ANCA; Etiology of primary vasculitis; Pathogenesis; Vasculitis

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; HYDRALAZINE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PENICILLAMINE;

ANCA ASSOCIATED VASCULITIS; CELLULAR IMMUNITY; DISEASE CLASSIFICATION; ENVIRONMENTAL FACTOR; GENETIC SUSCEPTIBILITY; GIANT CELL ARTERITIS; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTENSION; INCIDENCE; NONHUMAN; PATHOGENESIS; PRACTICE GUIDELINE; REVIEW; RHEUMATIC DISEASE; SENSITIVITY AND SPECIFICITY; SMALL VESSEL VASCULITIS; TISSUE NECROSIS; VASCULITIS;

ANIMALS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; HEPATITIS B; HEPATITIS C; HUMANS; SENSITIVITY AND SPECIFICITY; VASCULITIS;

EID: 80052825724     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.5459     Document Type: Review

References (127)

1. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 337: 1512-1523, 1997.
2. Reinhold-Keler E, Herlyn K, Wagner-Bastmeyer R, et al. Stable incidence of primary systemic vasculitides over five years: result from the German Vasculitis Register. Arthritis Rheum 53: 93-99, 2005.
3. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37: 187-192, 1994.
4. Frankel SK, Cosgrove GP, Fischer A, Meehan RT, Brown KK. Update in the diagnosis and management of pulmonary vasculitis. Chest 129: 452-465, 2006.
5. Brown KK. Pulmonary vasculitis. Proc Am Thorac Soc 3: 48-57, 2006.
6. Jennette JC, Falk RJ. New insight into the pathogenesis of vasculitis associated with antineutrophil cytoplasmic autoantibodies. Curr Opin Rheumatol 20: 55-60, 2008.
7. Seo P, Stone JH. Small-vessel and medium-vessel vasculitis. Arthritis Rheum 57: 1552-1559, 2007.
8. Kallenberg CG. Pathogenesis of PR3-ANCA associated vasculitis. J Autoimmun 30: 29-36, 2008.
9. Boomsma MM, Stegeman CA, van der Leij MJ, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 43: 2025-2033, 2000.
10. Segelmark M, Phillips BD, Hogan SL, et al. Monitoring proteinase 3 antineutrophil cytoplasmic antibodies detection of relapses in small vessel vasculitis. Clin Diagn Lab Immunol 10: 769-774, 2003.
11. Falk RJ, Jennette JC. ANCA Disease: Where is this field heading? J Am Soc Nephrol 21: 745-752, 2010.
12. Kettritz R, Jennette JC, Falk RJ. Crosslinking of ANCA-antigens stimulates superoxide release by human neutrophils. J Am Soc-Nephro 8: 386-394, 1997.
13. Xiao H, Heeringa P, Hu P, Liu Z, Falk RJ, Jennette JC. A major role for neutrophils in the induction of necrotising and crescentric glomerulonephritis by anti-myeloperoxidase IgG in mice. Kidney Blood Press Res 26: 255-262, 2003.
14. Savage CO. Vascular biology and vasculitis. APMIS (Suppl): 37-40, 2009.
15. Maugeri N, Rovere-Querini P, Baldini M, Sabbadini MG, Manfredi AA. Translational mini-review series on immunology of vascular disease: Mechanisms of vascular inflammation and remodelling in systemic vasculitis. Clinical and Experimental Immunology 156: 395-404, 2009.
16. Little MA, Savage CO. The role of the endothelium in systemic small vessel vasculitis. ClinExpRheumatol 26: 135-140, 2008.
17. Ma-Krupa W, Jeon MS, Spoerl S, Teder TF, Goronzy JJ, Weyand CM. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 199: 173-183, 2004.
18. Pryshchep O, Ma-Krupa W, Younge BR, Goronzy JJ, Weyand CM. Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation 118: 1276-1284, 2008.
19. Ntatsaki E, Watts RA, Scott DG. Epidemiology of ANCAassociated vasculitis. Rheum Dis Clin North Am 36: 447-461, 2010.
20. Watts RA, Scott DG. Epidemiology of the vasculitides. Semin Respir Crit Care Med 25: 455-464, 2004.
21. Fries JF, Hunder GG, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification vasculitis. Arthritis Rheum 33: 1135-1136, 1990.
22. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37: 187-192, 1994.
23. Lane SE, Watts RA, Barker THW, Scott DG. Evaluation of the Sorenson diagnostic criteria in classification systemic vasculitis. Rheumatology 41: 1138-1141, 2002.
24. Bruce IN, Bell AL. A comparision of two nomenclature systems for primary systemic vasculitis. Br J Rheumatol 36: 453-458, 1997.
25. Sorenson SF, Slot O, Tvede N, Petersen J. A prospective study of vasculitis patients collected in 5-year period: evaluation of the Chapel Hill nomenclature. Ann Rheum Dis 59: 478-482, 2000.
26. Watts R, Lane S, Hanslik T, et al. Development and validation of a concensus methodology for the classification of the ANCA associated and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66: 222-227, 2007.
27. Liu LJ, Chen F, Yu F, Zhao MH, Wang HY. Evaluation of a new algorithm in classification of systemic vasculitis. Rheumatology 47: 708-712, 2008.
28. Woywodt A, Matteson EL. Wegener's granulomatosis: Probing the told past of the man behind eponym. Rheumatology (Oxford) 45: 1303-1306, 2006.
29. Basu N, Watts R, Bajema I, et al. EULAR points to consider in development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis 69: 1744-1750, 2010.
30. Weyand CM, Gronzy JJ. Medium-and large-vessel vasculitis. N Engl J Med 349: 160-169, 2003.
31. Savige J, Gillis D, Benson E, et al. International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol 111: 507-513, 1999.
32. Rao JK, Weinberger M, Oddone EZ, Allen NB, Landsman P, Feussner JR. The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis. Ann Intern Med 123: 925-932, 1995.
33. Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 52: 2926-2935, 2005.
34. Sable-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 143: 632-663, 2005.
35. Kallenberg CG. Churg-Strauss syndrome: just one disease entity? Arthritis Rheum 52: 2589-2593, 2005.
36. Franssen CF, Stegeman CA, Kallenberg CG, et al. Antiproteinase 3-and antimyeloperoxidase-associated vasculitis. Kidney Int 57: 2195-2206, 2000.
37. Kallenberg CG, Heeringa P, Stegeman CA. Mechanisms of disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol 2: 661-670, 2006.
38. Marinaki O, Neumann I, Kalsch AI, et al. Abnormalities of CD4 T-cell subpopulations in ANCA-associated vasculitis. Clin Exp Immunol 140: 181-191, 2005.
39. Abdulahad WH, van der Geld YM, Stegeman CA, Kallenberg CG. Persistent expansion of CD4+ effector memory cells in Wegener granulomatosis. Kidney Int 70: 938-947, 2006.
40. Sakaguchi S, Setoguchi R, Yagi H, Nomura T. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in self-tolerance and autoimmune disease. Curr Top Microbiol Immunol 305: 51-66, 2006.
41. Abdulahad WH, Stegeman CA, van der Geld YM, et al. Functional defect of circulating regulatory CD4+ T cells in patients with Wegener granulomatosis in remission. Arthritis Rheum 56: 2080-2091, 2007.
42. Wilde B, Thewissen M, Damoiseaux J, Paasen P, Witzke O, Tervaert C. T cells in ANCA-associated vasculitis: what can we learn from lesional versus circulating T cells? Arthritis Research & Therapy 12: 204, 2010.
43. De Rosa V, Procaccini C, Cali G, et al. A key role of leptin in the control of regulatory T-cell proliferation. Immunity 26: 241-255, 2007.
44. Kumpers P, Horn R, Brabant G, et al. Serum leptin and ghrelin correlate with disease activity in ANCA associated vasculitis. Rheumatology 47: 484-487, 2008.
45. Thewissen M, Cohen Tervaert JW. Leptin and ANCA-associated vasculitis a healthy link? Rheumatology 47: 387-389, 2008.
46. Lamprecht P, Moosig F, Csernok E, et al. CD28 negative T cells are enriched in granulomatous lesions of the respiratory tract in Wegener's granulomatosis. Thorax 56: 751-757, 2001.
47. Moosing F, Csernok E, Wang G, Gross WL. Costimulatory molecules in Wegener granulomatosis: lack of expression of CD28 and preferential up-regulation of its ligands B7-1 (CD80) and B7-2 (CD86) on T-cells. Clin Exp Immunol 114: 113-118, 1998.
48. Steiner K, Moosig F, Csernok E, et al. Increased expression of CTLA-4 (CD152) by T and B lymphocytes in Wegener's granulomatosis. Clin Exp Immunol 126: 143-150, 2001.
49. Sanders JSF, Huitma MG, Kallenberg CGM, Stegeman CA. Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase3-neutrophil cytoplasmic antibodies: associations with disease activity and relapse. Ann Rheum Dis 65: 1484-1489, 2006.
50. Yeung RS. Kawasaki disease: update on pathogenesis. Curr Opin Rheumatol 22: 551-560, 2010.
51. Balding CEJ, Howie AJ, Drake Lee AB, Savage CO. Th2 dominance in nasal mucosa in patients with Wegener's granulomatosis. ClinExpImmunol 125: 332-339, 2001.
52. Csernok E, Trabandt A, Muller A, et al. Cytokine profiles in Wegener granulomatosis-Predominance of type 1 (th1) in the granulomatous inflammation. Arthritis Rheum 42: 742-750, 1999.
53. Kiene A, Csernok E, Muller A, et al. Elevated interleukin-4 and interleukin-13 production by cell lines from patients with Churg-Strauss syndrome. Arthritis Rheum 44: 469-473, 2001.
54. Zhao C, Yang P, He H, et al. S-antigen specific T helper type 1 response is present in Behcet's disease. Mol Vis 14: 1456-1464, 2008.
55. Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 23: 906-915, 2010.
56. Abdulahad WH, Stegeman CA, Limburg PC, Kallenberg CG. Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission. Arthritis Rheum 58: 2196-2205, 2008.
57. Saito H, Tsurikiawa N, Tsuburai T, Oshikata C, Akiyama K. Cytokine production profile of CD4+ T-cells from patients with active Churg-Strauss syndrome tends toward Th17. Int Arch Allergy Immunol 49: 61-65, 2009.
58. Lamprecht P, Bruhl H, Erdmann A, et al. Heterogeneity of CD4+ and CD8+ memory T cells in localized and Wegener's granulomatosis. Arthritis Res Ther 5: R25-R31, 2003.
59. Co DO, Hogan LH, II-Kim S, Sandor M. T cell contributions to the different phases of granuloma formation. Immunol Lett 92: 135-142, 2004.
60. Wilde B, van Paassen P, Damoiseaux J, et al. Dendritic cells in renal biopsies of patients with ANCA-associated vasculitis. Nephrol Dial Transplant 24: 2151-2156, 2009.
61. Aloisi F, Pujol-Borrelll R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 6: 205-217, 2006.
62. Finkielman JD, Merkel PA, Schroeder D, et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 147: 611-619, 2007.
63. Wegener's Granulomatosis; Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352: 351-361, 2005.
64. Boomsma MM, Stegeman CA, van der Leij MJ, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 43: 2025-2033, 2000.
65. Bansal PJ, Tobin MC. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol 93: 398-401, 2004.
66. Kallenberg CGM. Pathophysiology of ANCA-associated small vessel vasculitis. Curr Rheumatol Rep 12: 399-405, 2010.
67. Falk RJ, Terrell R, Charles LA, Jennette JC. Antineutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals. Proc Natl Acad Sci USA 87: 4115-4119, 1990.
68. Rarok AA, Limburg PC, Kallenberg CG. Neutrophil-activating potential of antineutrophil cytoplasm autoantibodies. J Leukoc Biol 74: 3-15, 2003.
69. Schreiber A, Rolle S, Peripelittchenko L, et al. Phosphoinositol-3-kinase-gamma mediates antineutrophil cytoplasmic autoantibodyinduced glomerulonephritis. Kidney Int 77: 118-128, 2010.
70. Schreiber A, Xiao H, Jennette JC, et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 20: 289-298, 2009.
71. Xing GQ, Chen M, Liu G, et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol 29: 282-291, 2009.
72. Radford DJ, Savage CO, Nash GB. Treatment of rolling neutrophils with antineutrophil cytoplasmic antibodies causes conversion to firm integrin-mediated adhesion. Arthritis Rheum 43: 1337-1345, 2000.
73. Nolan SL, Kalia N, Nash GB, et al. Mechanisms of ANCAmediated leukocyte-endothelial cell interactions in vivo. J Am Soc Nephrol 19: 973-984, 2008.
74. Kessenbrock K, Krumholz M, Schonnermark U, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 15: 623-625, 2009.
75. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110: 955-963, 2002.
76. Schreiber A, Xiao H, Falk RJ, Jennette JC. Bone-marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by antimyeloperoxidase antibodies. J Am Soc Nephrol 17: 3355-3364, 2006.
77. Xiao H, Schreiber A, Heeringa P, et al. Alternative complement pathway in pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 170: 52-64, 2007.
78. van Timmerman MM, van der Veen BS, Stegeman CA, et al. IgG glycan hydrolysis attenuates ANCA-mediated glomerulonephritis. J Am SocNephrol 21: 1103-1114, 2010.
79. Pfister H, Ollert M, Frohlich LF, et al. Anti-neutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 104: 1411-1418, 2004.
80. van der Geld YM, Hellmark T, Selga D, et al. Rats and mice immunized with chimeric human/mouse proteinase 3 produce autoantibodies to mouse Pr3 and rat granulocytes. Ann Rheum Dis 66: 1679-1682, 2007.
81. Pendergraft WF 3rd, Preston GA, Shah RR, et al. Autoimmunity is triggered by c PR-3 (105-201), a protein complementary to human autoantigen proteinase-3. Nat Med 10: 72-79, 2004.
82. Yang JM, Bautz DJ, Lionaki S, et al. ANCA patients have T cells responsive to complementary PR-3 antigen. Kidney Int 74: 1159-1169, 2008.
83. Savige J, Nassis L, Cooper T, et al. Antineutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis after immunisation with bacterial proteins. Clin Exp Rheumatol 20: 783-789, 2002.
84. Kain R, Exner M, Brandes R, et al. Molecular mimicry in pauciimmune focal necrotizing glomerulonephritis. Nat Med 14: 1088-1096, 2008.
85. Dillon JM, Eleftheriou D, Brogan P. Medium-size-vessel vasculitis. Pediatr Nephrol 25: 1641-1652, 2010.
86. Guillevin L, Mahr A, Callard P, et al. Hepatitis B virus-associated polyarteritisnodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 84: 313-322, 2005.
87. Finkel TH, Torok TJ, Ferguson PJ, et al. Chronic parvovirus infection and systemic necrotising vasculitis: opportunistic infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent? Lancet 343: 1255-1258, 1994.
88. Golden Mp, Hammer SM, Wanke CA, Albrecht MA. Cytomegalovirus vasculitis. Case reports and review of the literature. Medicine (Baltimore) 73: 246-255, 1994.
89. Pagnoux C, Cohen P, Guillevin L. Vasculitides secondary to infections. Clin Exp Rheumatol 24 (Suppl 4): S71-S81, 2006.
90. Lidar M, Lipschitz N, Langevitz P, Shoenfeld Y. The infectious etiology of vasculitis. Autoimmunity 42: 432-438, 2009.
91. Charles ED, Dustin LB. Hepatitis C virus-induced cryoglobulinemia. Kidney Int 76: 818-824, 2009.
92. Ferri C. Mixed cryoglobulinemia. Orphanet J Rare Dis 3: 25, 2008.
93. Knight A, Sandin S, Askling J. Risks and relative risks of Wegener's granulomatosis among close relatives of patients with disease. Arthritis Rheum 58: 302-307, 2008.
94. Wilcocks L, Lyons PA, Rees AJ, Smith GC. The contribution of genetic variation and infection to the pathogenesis of ANCAassociated systemic vasculitis. Arthritis. Research & Therapy 12: 202-213, 2010.
95. Carr EJ, Clatworthy MR, Lowe CE, et al. Contrasting genetic association of IL2RA with SLE and ANCA-associated vasculitis. BMC Med Genet 10: 22, 2009.
96. Preston GA, Ciavatta D, Yang JJ, et al. Normal gene silencing mechanisms in mature neutrophils are distrupted in ANCA vasculitis. APMIS 117: 122-123, 2009.
97. Hsueh KC, Lin YJ, Chang JS, et al. Influence of interleukin 18 promoter polymorphisms in susceptibility to Kawasaki disease in Taiwan. J Rheumatol 35: 1408-1413, 2008.
98. Onouchi Y, Gunji T, Burns JC, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary aneurysms. Nat Genet 40: 35-42, 2008.
99. Matsubara K, Fukaya T, Schibayama N, et al. Development of serum IgM antibodies against superantigens of Staphylococcus aureus and Streptococcus pyogenes in Kawasaki disease. Clin Exp Immunol 143: 427-434, 2006.
100. Mahr AD, Neogi T, Merkel PA. Epidemiology of Wegener's granulomatosis: lessons from descriptive studies and analyses of genetic and environmental risk determinants. Clin Exp Rheumatol 24: S82-S91, 2006.
101. Hogan SL, Cooper GS, Savitz DA, et al. Association of silica exposure with anti-neutrophil cytoplasmic autoantibody small-vessel vasculitis, a population based case-control study. Clin J Am Soc Nephrol 2: 290-299, 2007.
102. Hagen EC, et al. Hypothesis on the etiology of antineutrophil cytoplasmic autoantibody associated vasculitis: the cause is hidden, but the result is known. Clin J Am Soc Nephrol 3: 237-252, 2008.
103. Short AK, Lockwood CM. Antigen specificity in hydralazine associated ANCA positive systemic vasculitis. QJ Med 88: 775-783, 1995.
104. Daniel CL. Leucocytoclastic vasculitis and Henoch-Schonlein purpura. Arthritis & Allied Conditions 86: 1793-1797, 2005.
105. Kim JH, Moon JI, Kim JE, et al. Cutaneous leukocytoclastic vasculitis due to antituberculosis medications, rifampin and pyrazinamide. Allergy Asthma Immunol Res 2: 55-58, 2010.
106. Mahaian A, Sharma R. Cox-2 selective nonsteroidal antiinflammatory drugs: current status. J Assoc Physicians India 53: 200-204, 2005.
107. Garcia-Marcos L, Schuster A, Perez-Yarza EG. Benefit-risk assessment of antileukotriens in management of asthma. Drug Saf 26: 483-518, 2003.
108. Maugeri N, Rovere-Querini P, Baldini M, Sabbadini MG, Manfredi AA. Translational mini review series on immunology of vascular disease: Mechanisms of vascular inflammation and remodelling in systemic vasculitis. Clin Exp Immunol 156: 395-404, 2009.
109. Tang PC, Qin L, Zienlonka J, et al. MyD88-dependent, superoxide initiated inflammation is necessary for flow-mediated inward remodelling of conduit arteries. J Exp Med 205: 3159-3171, 2008.
110. Rock KL, Kono H. The inflammatory response to cell death. Annu Rev Pathol 3: 99-126, 2008.
111. Song H, Feng Y, Hoeger S, et al. High mobility group box 1 abd adenosine are released by endothelial cells during hypothermic preservation. Clin Exp Immunol 152: 311-319, 2008.
112. Chavakis E, Hain A, Vinci M, et al. High mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res 100: 204-212, 2007.
113. Bianchi ME, Manfredi AA. High mobility group box 1 (HMGB 1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 220: 35-46, 2007.
114. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatic and giant-cell arteritis. Lancet 372: 234-245, 2008.
115. Sato F, Maruyama S, Hayashi H, et al. High mobility group box chromosomal protein 1 in patients with renal disease. Nephron Clin Pract 108: 194-201, 2008.
116. Frankel SK, Cosgrove GP, Brown KK. Small vessel vasculitis of the lung. Chron Respir Dis 2: 75-84, 2005.
117. Langford CA. Vasculitis. J Allergy Clin Immunol 125: 216-225, 2010.
118. Cacoub P, Saadoun D. Hepatitis C virus infection induced vasculitis. Clin Rev Allergy Immunol 35: 30-39, 2008.
119. Ferri C, Mascia MT. CryoglobulinemicVasculitis: Review. Curr Opin Rheumatology 18: 54-63, 2006.
120. Brogan P, Eleftheriou D, Dillon M. Small vessel vasculitis. Pediatr Nephrol 25: 1025-1035, 2010.
121. Gulati A, Bagga A. Large vessel vasculitis. Pediatr Nephrol 25: 1037-1048, 2010.
122. Tervaert C. Translational mini-review series on immunology of vascular disease: accelerated atherosclerosis in vasculitis. Clin Exp Immunol 156: 377-385, 2009.
123. Hanson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl Med 352: 1685-1695, 2005.
124. Taleb S, Tedgui A, Mallat Z. Regulatory T-cell immunity and its relevance to atherosclerosis. J Intern Med 263: 489-499, 2008.
125. Pagnoux C, Hogan SL, Chin H. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparision of two independent cohorts. Arthritis Rheum 58: 2908-2918, 2008.
126. Flossmann O, Bacon P, de Groot K. Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis 66: 283-292, 2007.
127. Seo P, Jayne D, Luqmani R, Merkel PA. Asessment of damage in vasculitis: expert ratings of damage. Rheumatology (Oxford) 48: 823-827, 2008.